Technical Analysis for PDSB - PDS Biotechnology Corporation
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.02 | 6.49% | 0.25 |
Earnings due: May 15
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 6.49% | |
| Weak + Overbought | Other | 6.49% |
| Alert | Time |
|---|---|
| 1.5x Volume Pace | about 14 hours ago |
| 50 DMA Resistance | about 14 hours ago |
| Possible Pocket Pivot | about 14 hours ago |
| Up 2 ATRs | about 14 hours ago |
| Rose Above Upper Bollinger Band | about 15 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/15/2024
PDS Biotechnology Corporation Description
PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Oncology Cancer Immunotherapy Breast Cancer Immunotherapies Prostate Cancer Melanoma Treatment Of Breast Cancer Lipid Oncolytics Biotech Head And Neck Cancer Cervical Cancer Anal Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.27 |
| 52 Week Low | 2.59 |
| Average Volume | 999,486 |
| 200-Day Moving Average | 4.93 |
| 50-Day Moving Average | 4.13 |
| 20-Day Moving Average | 3.29 |
| 10-Day Moving Average | 3.60 |
| Average True Range | 0.32 |
| RSI (14) | 60.47 |
| ADX | 28.21 |
| +DI | 33.42 |
| -DI | 16.66 |
| Chandelier Exit (Long, 3 ATRs) | 3.39 |
| Chandelier Exit (Short, 3 ATRs) | 3.56 |
| Upper Bollinger Bands | 4.07 |
| Lower Bollinger Band | 2.51 |
| Percent B (%b) | 0.97 |
| BandWidth | 47.24 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.17 |
| MACD Histogram | 0.1543 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.22 | ||||
| Resistance 3 (R3) | 5.20 | 4.78 | 5.02 | ||
| Resistance 2 (R2) | 4.78 | 4.47 | 4.79 | 4.95 | |
| Resistance 1 (R1) | 4.40 | 4.29 | 4.59 | 4.42 | 4.89 |
| Pivot Point | 3.98 | 3.98 | 4.07 | 3.99 | 3.98 |
| Support 1 (S1) | 3.60 | 3.67 | 3.79 | 3.62 | 3.15 |
| Support 2 (S2) | 3.18 | 3.49 | 3.19 | 3.09 | |
| Support 3 (S3) | 2.80 | 3.18 | 3.02 | ||
| Support 4 (S4) | 2.82 |
